Harvard Bioscience
HBIO
77 hedge funds and large institutions have $78.9M invested in Harvard Bioscience in 2013 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 53 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 81 → 77 (-4)
6% less capital invested
Capital invested by funds: $83.6M → $78.9M (-$4.76M)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
64% less call options, than puts
Call options by funds: $5K | Put options by funds: $14K
74% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.72M |
| 2 |
CCP
Centaur Capital Partners
Southlake,
Texas
|
+$1.14M |
| 3 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
+$785K |
| 4 |
WIC
Woodmont Investment Counsel
Nashville,
Tennessee
|
+$297K |
| 5 |
VDBMI
Van Den Berg Management I
Austin,
Texas
|
+$292K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$3.04M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.05M |
| 3 |
FCAM
F&C Asset Management
Edinburgh, Scotland,
United Kingdom
|
-$1.88M |
| 4 |
HSA
Hussman Strategic Advisors
Ellicott City,
Maryland
|
-$1.7M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.22M |
HBIO Hedge Fund Activity: Q4 2013 in Review
77 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q4 2013, worth a combined $78.9M — down 5.7% from $83.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of HBIO and 10 opened new positions — a net loss of 3 holders — while 53 trimmed existing stakes and 14 added.
The largest buyer was Granahan Investment Management, adding an estimated $1.72M. The largest seller was BlackRock Institutional Trust, cutting an estimated $3.04M.
- 77 institutional investors held Harvard Bioscience (HBIO) as of Q4 2013, down from 81 in Q3 2013.
- Funds reported $78.9M of Harvard Bioscience stock for Q4 2013, down 5.7% quarter-over-quarter.
- 10 funds opened new Harvard Bioscience positions in Q4 2013 and 13 closed out, a net change of -3 holders.
- The largest Harvard Bioscience buyer in Q4 2013 was Granahan Investment Management, an estimated $1.72M added.
- The largest Harvard Bioscience seller in Q4 2013 was BlackRock Institutional Trust, an estimated $3.04M sold.
Based on aggregated 13F filings for Q4 2013.